{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:23:51Z","timestamp":1788481431981,"version":"build-2803163510"},"reference-count":36,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3_Suppl","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,9]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>Acknowledging the fallibilities of recalling events from more than three decades ago, the recollection of Richard Carter\u2019s impact on the identification and development of Pfs25, a major surface protein of <jats:italic>Plasmodium falciparum<\/jats:italic> zygotes and ookinetes, and target of malaria transmission-blocking vaccines, remains unassailable. In fondest memories of Richard Carter\u2019s many contributions, herein retells some memorable events along the tortuous journey toward the development of Pfs25 vaccines.<\/jats:p>","DOI":"10.4269\/ajtmh.21-1326","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T12:36:39Z","timestamp":1657542999000},"page":"32-35","source":"Crossref","is-referenced-by-count":5,"title":["Efforts to Develop Pfs25 Vaccines"],"prefix":"10.4269","volume":"107","author":[{"given":"David C.","family":"Kaslow","sequence":"first","affiliation":[{"name":"PATH Essential Medicines, PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Exp Parasitol","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0014-4894(58)90036-5","article-title":"Changes in infectiousness of malarial gametocytes: II. Analysis of the possible causative factors","volume":"7","year":"1958"},{"key":"b2","series-title":"Nature","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/263057a0","article-title":"Malaria transmission blocked by immunisation with gametes of the malaria parasite","volume":"263","year":"1976"},{"key":"b3","series-title":"Science","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.959832","article-title":"Malaria: successful immunization against the sexual stages of Plasmodium gallinaceum","volume":"193","year":"1976"},{"key":"b4","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1128\/iai.45.3.775-777.1984","article-title":"A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies","volume":"45","year":"1984"},{"key":"b5","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1084\/jem.162.5.1460","article-title":"Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito","volume":"162","year":"1985"},{"key":"b6","series-title":"Nature","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/333074a0","article-title":"A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains","volume":"333","year":"1988"},{"key":"b7","series-title":"Vaccines, from Concept to Clinic: A Guide to the Development and Clinical Testing of Vaccines for Human Use","year":"1999"},{"key":"b8","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals","volume":"174","year":"1991"},{"key":"b9","series-title":"Biotechnology (N Y)","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nbt0594-494","article-title":"Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose","volume":"12","year":"1994"},{"key":"b10","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1128\/IAI.68.10.5530-5538.2000","article-title":"A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies","volume":"68","year":"2000"},{"key":"b11","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/S0264-410X(02)00701-6","article-title":"Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials","volume":"21","year":"2003"},{"key":"b12","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1128\/IAI.01539-07","article-title":"Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates","volume":"76","year":"2008"},{"key":"b13","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1016\/j.vaccine.2010.08.022","article-title":"Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen","volume":"28","year":"2010"},{"key":"b14","series-title":"Hum Vaccin","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/hv.7.0.14588","article-title":"Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity","volume":"7","year":"2011"},{"key":"b15","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e37179","DOI":"10.1371\/journal.pone.0037179","article-title":"Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission","volume":"7","year":"2012"},{"key":"b16","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1128\/IAI.01438-13","article-title":"Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding","volume":"82","year":"2014"},{"key":"b17","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults","volume":"36","year":"2018"},{"key":"b18","series-title":"Proc Natl Acad Sci USA","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1073\/pnas.0609885104","article-title":"Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25","volume":"104","year":"2007"},{"key":"b19","series-title":"Proc Natl Acad Sci USA","doi-asserted-by":"publisher","first-page":"18243","DOI":"10.1073\/pnas.0608545103","article-title":"Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex","volume":"103","year":"2006"},{"key":"b20","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","year":"2013"},{"key":"b21","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and immunogenicity of Pfs25-EPA\/Alhydrogel\u00ae, a transmission blocking vaccine against Plasmodium falciparum: an open label study in malaria na\u00efve adults","volume":"11","year":"2016"},{"key":"b22","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1128\/iai.62.12.5576-5580.1994","article-title":"Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.","volume":"62","year":"1994"},{"key":"b23","series-title":"Science","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1126\/science.1925544","article-title":"Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus","volume":"252","year":"1991"},{"key":"b24","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1128\/iai.64.9.3833-3844.1996","article-title":"NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"64","year":"1996"},{"key":"b25","series-title":"J Infect Dis","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","year":"1998"},{"key":"b26","series-title":"Infect Immun","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/IAI.67.4.1688-1693.1999","article-title":"Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies","volume":"67","year":"1999"},{"key":"b27","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e29428","DOI":"10.1371\/journal.pone.0029428","article-title":"A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity","volume":"6","year":"2011"},{"key":"b28","series-title":"Malar J","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12936-017-1896-7","article-title":"New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission","volume":"16","year":"2017"},{"key":"b29","series-title":"Front Immunol","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fimmu.2019.00730","article-title":"Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming","volume":"10","year":"2019"},{"key":"b30","series-title":"Front Immunol","doi-asserted-by":"publisher","first-page":"694759","DOI":"10.3389\/fimmu.2021.694759","article-title":"Safety and immunogenicity of ChAd63\/MVA Pfs25-IMX313 in a phase I first-in-human trial","volume":"12","year":"2021"},{"key":"b31","series-title":"Malaria Immunol","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000058850","article-title":"Transmission-blocking vaccines","volume":"80","year":"2002"},{"key":"b32","series-title":"Mol Biochem Parasitol","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0166-6851(89)90134-5","article-title":"Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum.","volume":"32","year":"1989"},{"key":"b33","series-title":"Science","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1126\/science.2902690","article-title":"Limited immunological recognition of critical malaria vaccine candidate antigens","volume":"242","year":"1988"},{"key":"b34","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.169.1.135","article-title":"Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies","volume":"169","year":"1989"},{"key":"b35","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1038\/s41467-019-11980-6","article-title":"Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25","volume":"10","year":"2019"},{"key":"b36","series-title":"Front Immunol","doi-asserted-by":"publisher","first-page":"732667","DOI":"10.3389\/fimmu.2021.732667","article-title":"Poor CD4+ T cell immunogenicity limits humoral immunity to P. falciparum transmission-blocking candidate Pfs25 in humans","volume":"12","year":"2021"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/3_Suppl\/article-p32.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/3_Suppl\/article-p32.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/3_Suppl\/article-p32.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T14:22:54Z","timestamp":1662733374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/3_Suppl\/article-p32.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":36,"journal-issue":{"issue":"3_Suppl"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.21-1326","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}